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Therapy-induced cellular senescence describes the phenomenon of cell cycle arrest that can be invoked in cancer cells in
responsetochemotherapy.Sustainedproliferativearrestisoftenovercomeasacontingentofsenescenttumorcellscanbypass
this cell cycle restriction. The mechanism regulating cell cycle re-entry of senescent cancer cells remains poorly understood.
Thisis the ﬁrst report ofthe isolationand characterization of twodistinct transitionalstates inchemotherapy-induced senescent
cellsthatshareindistinguishablemorphologicalsenescencephenotypesandarefunctionallyclassiﬁedbytheirabilitytoescape
cellcyclearrest.Ithasbeenobservedthatcellsurfaceexpression ofcoxsackieandadenovirusreceptor(CAR)isdownregulated
in cancer cells treated with chemotherapy. We show the novel use of surface CAR expression and adenoviral transduction to
differentiate senescent states and also show in vivo evidence of CAR downregulation in colorectal cancer patients treated with
neoadjuvant chemoradiation. This study suggests that CAR is a candidate biomarker for senescence response to antitumor
therapy, and CAR expression can be used to distinguish transitional states in early senescence to study fundamental regulatory
events in therapy-induced senescence.
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Cellular senescence, elicited physiologically by telomere
attrition, can also be triggered by DNA damage and selected
oncogenic signals.
1–4 In pre-cancerous states such as
melanocytic nevus or dysplastic Barrett’s esophagus, cellular
senescencehasbeen postulated to enforcegrowtharrestand
functionally suppress tumor transformation.
5–8 Activation of
tumor suppressor pathways mediated by p53 and pRB is
typically required for the induction and maintenance of the
senescent response.
9–11 Unfortunately, neoplastic cells can
bypass cell cycle restriction through mutational, epigenetic
or functional inactivation of p53 and pRB pathways during
carcinogenesis to resume proliferation.
9,10,12 For example,
nonrandom gains of chromosomes 5q, 8q and 10 in prostate
epithelial cells have been shown to have a key role in
senescence bypass (or escape) in the pathogenesis of
prostate cancer.
12
Therapy-induced cellular senescence has been shown in a
variety of in vitro and in vivo models and in human tumor
samples.
1,13–16 Despite the inactivation of p53 and p16
INK4a/
pRB pathways in the majority of human cancer types,
chemotherapeutic drugs and ionizing radiation can elicit
robust senescence responses in many tumor cell
lines.
1,11,17,18 Senescent cells are characterized by sustained
proliferative arrest, morphological changes and expression of
the classical senescence marker, pH-restricted, senescence-
associated b-galactosidase (SA-b-gal). Escape from therapy-
induced senescence has been shown, but the mechanism
regulating cell cycle re-entry of senescent cell remains poorly
understood. In chemotherapy-treated senescent p53-null
and p16-deﬁcient NCI-H1299 cells, we have shown that
senescence escape is closely associated with the aberrant
over-expressionofthecyclin-dependentkinaseCdc2/Cdk1.
19
In an effort to gain a better understanding of this biological
barrier, we sought to further characterize early events during
senescence escape. This is the ﬁrst descriptive report of the
isolation andcharacterizationoftwodistincttransitionalstates
in chemotherapy-induced senescence distinguished by the
ability of senescent cells to escape cell cycle arrest. Despite
sharing indistinguishable morphological senescence pheno-
types, the two states can be differentiated by their surface
expression of Coxsackie and adenovirus (Adv) receptor
(CAR).
CAR is a 46-kDa glycosylated transmembrane protein
associated with tight junction complexes and appears to have
important roles in embryonic development, cell–cell adhesion
and intercellular recognition.
20,21 Cell surface CAR expres-
sion enables viral attachment by its interaction with the Adv
ﬁnger-knob protein and functions to regulate viral uptake,
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22,23 Recently, CAR knock-
down in a colon cancer line has been shown to strongly
downregulate a-catenin and alter cellular morphology,
increase cell proliferation and enhance cell migration and
invasion.
24 CAR is ubiquitously expressed in many normal
epithelial tissues, but its expression appears to vary in tumor
tissues with advanced grade, stage and increased metastatic
potential.
24,25
In this report, we show that surface CAR downregulation is
a consistent feature observed in multiple cell lines during
chemotherapy-induced senescence. Using either surface
CAR expression or a marker Adv transduction as a surrogate
determinant for CAR, senescent cell populations can be
identiﬁed and separated into two morphologically indistin-
guishable subpopulations that functionally differ by their
ability to escape senescence. The subpopulation of senes-
cent cells, characterized by high surface CAR expression,
retains the ability to escape cell cycle arrest. Conversely, low
CAR-expressing senescent cells are conﬁned to a prolonged
senescent state and destined for eventual cell death. The
biological events underlying the transition between these two
states constitute a signiﬁcant biological barrier that deter-
mines the reversibility of therapy-induced senescence and
cell fate. We also provide evidence of downregulation of
surface CAR in human rectal cancer specimens following
neoadjuvant (preoperative) chemotherapy and radiation.
Altogether, our work proposes CAR as a novel biomarker for
senescence in response to antitumor therapy, and that
surface CAR expression may be a means for isolating distinct
transitional states within therapy-induced senescence whose
biological differences may yield novel insights into barriers of
senescence.
Results
Chemotherapy-induced senescent cells downregulate
surface expression of CAR. Previous studies have shown
that cells in replicative senescence may become less
susceptible to adenoviral infection as a result of surface CAR
downregulation.
26,27 We therefore sought to determine
whether CAR is similarly downregulated in therapy-induced
senescent cells in an established tissue culture system.
19 In
the schema depicted in Figure 1a, immortalized cancer
cells adopt a state of prolonged arrest and exhibit classical
senescence phenotype within 2–6 days following an
abbreviated exposure to moderate concentrations of
chemotherapy. For example, 30% of H1299 cells treated with
camptothecin (CPT) at 0.3–2  IC50 for 3 days remain viable
upon release into fresh media. Among these cells, 470–80%
become morphologically senescent and expresses the
senescence marker SA-b-gal. These senescent cells persist
for up to 3 weeks, during which infrequent cells escape cell
cycle arrest to form proliferative colonies. To determine
whether surface CAR is downregulated during therapy-
induced senescence, we performed immunoﬂuorescence
staining with anti-CAR antibody in unﬁxed, non-permeabilized
cells. Three independent tumor lines including H1299 (lung),
HCT 116 (colon) and BxPC-3 (pancreas) were treated
with either CPT or doxorubicin, recovered and examined by
ﬂow-activated cell sorting (FACS) analysis (Figure 1b and
Supplementary Figure 1A). All three cell lines exhibited
consistent and signiﬁcant (475%) reduction of their surface
CAR expression over a period of 6 days in senescence. The
reduction of surface CAR expression appears to be the result
of membrane protein downregulation as the total cellular CAR
level is found to be only modestly reduced over this same
period of time (Supplementary Figures 1B and C).
Therapy-induced senescent cells lose susceptibility
to adenoviral infection as a result of surface CAR
downregulation. CAR expression has been shown to
correlate with the efﬁciency of adenoviral-mediated
transduction in a variety of human malignancies, including
glioma, melanoma, lung and pancreatic cancer.
28–31
Following their release from chemotherapy exposure, we
have observed that senescent cells become progressively
resistant to adenoviral infection. As shown in Figure 2a,
signiﬁcant numbers of H1299 tumor cells on day 4 fail to
express the marker red ﬂuorescence protein (RFP) after a 4h
infection with Adv harboring the RFP transgene (Adv-RFP).
In contrast, nearly all untreated cells express RFP after
identical Adv-RFP infection. Quantitative FACS analysis
further shows that senescent cells of all three tumor lines
become progressively resistant to Adv-RFP marking
(Figure 2b and Supplementary Figure 2A). In each case,
the percentage of RFP-expressing cells following marker
virus infection declines by at least 75% over 6 days. Using
the uninfected senescent tumor cells to set FACS gating,
Adv-RFP-infected cells can be differentiated as either
‘marked’ cells (i.e., RFP expression above the uninfected
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Figure 1 Surface CAR expression in senescent H1299, HCT 116 and BxPC-3
cells. (a) Therapy-induced senescence in vitro schema: tumor cells are treated for
3 days ( 3 to 0) with CPT (30nM for H1299; 120nM for BxPC-3) or doxorubicin
(150nM for HCT 116) and rinsed on day 0. Fresh media replaced (D) every 7 days
until theformationof colonieswithin14–21days. Classicalsenescence morphology
is observed between days 2 and 6. (b) Quantitative histogram of cell surface CAR
expression by immunostaining with anti-CAR antibody and FACS analysis. Untx
represents untreated cells. Error bars denote standard deviation of three
independent experiments (N¼3)
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Cell Death and Diseasebaseline) or as ‘unmarked’ cells (i.e., RFP expression
at or below the baseline). The marked and unmarked
senescent cells are otherwise indistinguishable in their
morphological features and SA-b-gal expression
(Supplementary Figure 2B).
We next determined a correlation between surface CAR
expression and adenoviral susceptibility through a regression
analysis using Adv-RFP marking data derived from all three
tumor lines and their surface CAR expression (Figure 3a). We
found that adenoviral marking correlated closely with CAR
expression with a linear correlation coefﬁcient (r
2) of 0.891
and P-value of 0.00054, thereby supporting a linear relation-
ship of these events. To further study this correlation,
senescent H1299 cells harvested 4 days following CPT
treatment were sorted into low and high CAR-expressing
populations (Figure 3b). The two sorted cell populations were
then recovered in fresh media, infected with the marker Adv-
RFP and analyzed for RFP expression. The results showed
threefold greater Adv-RFP marking (67%) in the high CAR-
expressing cells as compared with only 22% marking in the
low CAR-expressing cells. Moreover, the anti-CAR antibody
in logarithmically increasing concentrations can block adeno-
viral marking of H1299 cells (Figure 3c). Linear regression
analysis of this experiment resulted in an r
2 coefﬁcient of 0.99
and y-intercept of 0.057. Altogether, these ﬁndings conﬁrm
CAR to be the dominant receptor that determines Adv entry
into tumor cells and validate the use of adenoviral marking as
a surrogate for surface CAR expression in therapy-induced
senescent cells.
CAR expression and adenoviral marking is cell cycle
independent. It is feasible that the gradual loss of CAR
expression and adenoviral marking in therapy-induced
senescent cells may be explained by the resistance
of senescent cells arrested at G2/M to Adv infection. To
determine whether CAR expression and adenoviral marking
correlate with cell cycle, we performed a gated analysis of
adenoviral marking and CAR expression (Figure 4a).
Untreated proliferating H1299 cells were either immuno-
stained with anti-CAR antibody or marked with Adv harboring
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Figure 2 Susceptibility of therapy-induced senescent H1299, HCT 116 and BxPC-3 cells to Adv-RFP infection: H1299, BxPC-3, and HCT 116 cells were treated as
described in Figure 1 and infected with Adv-RFP at indicated days and resultant RFP expression determined by FACS analysis. (a) Phase-contrast and ﬂuorescence
microscopy images ( 40) of proliferating and senescent (day 4) H1299 cells. Asterisks indicate ‘unmarked’ senescent cells lacking RFP expression. (b) Histogram of gated
results of ‘marked’ RFP-transduced senescent cells. Data points are shown as mean with error bars representing standard deviation of three independent experiments
(N¼3). Asterisks (*) indicate ‘unmarked’ senescent cells lacking RFP expression
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Cell Death and Diseasethe green ﬂuorescence protein transgene (Adv-GFP) before
ﬁxation and staining with propidium iodide. These cells were
gated by FACS to determine either the Adv-GFP marking or
the CAR expression in ungated (total), G1 and G2/M
fractions. We found that nearly 100% of G1 and G2/M cells
express GFP and CAR. We also induced cell cycle arrest
at G1 by serum starvation for 72h, which resulted in a
predominant but incomplete G1 arrest and at G2/M with
20nM nocodazole (Figure 4b). Untreated and arrested cells
were then infected with Adv-GFP or immunostained for CAR.
As shown in Figure 4b, between 89 and 100% of arrested
cells expressed CAR and were marked by Adv-GFP. These
results show that features of CAR expression and adenoviral
susceptibility are cell cycle independent and represent a
biological property of therapy-induced cellular senescence.
Escape from replicative arrest preferentially occurs in
the marked senescent cells. In addition to their
indistinguishable morphological features, marked and
unmarked senescent cells retain their membrane integrity
and cellular viability (Supplementary Figures 2B and 3). To
determine whether escape occurs preferentially from either
the marked or the unmarked senescent cell populations, we
sorted Adv-RFP marked, senescent H1299 cells at indicated
time points following CPT exposure (Figure 5a). On day 4,
FACS sorting efﬁciently separate marked and unmarked
senescent cells based on gates predeﬁned with
corresponding uninfected senescent control (Figure 5a, top
panel). Equal numbers (5 10
4) of sorted cells from marked
and unmarked subpopulations from days 2, 4 and 6 were
released into fresh media and allowed to form colonies for
an additional 14–21 days. Substantially greater numbers of
escape colonies were observed to form from the marked cell
population (table in Figure 5a). In contrast, between 10- and
150-fold fewer colonies formed from the unmarked sorted
cells. A representative example of a day 4 colony formation
assay is shown (picture in Figure 5a). FACS sorting was
noted to become less efﬁcient on day 6, likely attributable to
greater pleomorphism and cellular complexity of senescent
cells with time. We speculate that the small but signiﬁcant
increase in colony formation from day 6 unmarked cells is the
result of declined sorting efﬁciency. As a complimentary
approach, we examined colonies derived from the senescent
H1299 cells infected with marker Adv harboring the bacterial
LacZ transgene on days 4 and 6. In situ b-galactosidase
(pH 7.0) assay was carried out to determine marker protein
expression during early colony formation (Figure 5b and
Supplementary Figure 4A). We reasoned that if colonies can
form equally from both senescent states as differentiated by
viral marking, then the frequency of detectable colonies
(Figure 5b ‘expected’) should mirror the proportion of marked
cells shown in Figure 2b, which steadily decreases from days
0 to 6. However, we found that every colony examined (25/25)
at each time point exhibits detectable marker expression with
an overall frequency of 100% (Figure 5b ‘results’). This ﬁnding,
in combination with the data obtained from the colony
formation assay in Figure 5a, suggests that escape colonies
are derived exclusively from the marked cell subpopulation.
CAR expression and adenoviral marking consequently deﬁne
two functionally different subpopulations of senescent cells
with opposing cell cycle re-entry potential and cell fates.
The conversion from a ‘marked’ to an ‘unmarked’ state
occurs during senescence. The dramatic differences in
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Figure 3 Relationship of adenoviral marking and CAR expression. (a) Linear
regression analysis of CAR expression and Adv-RFP infectivity of H1299, HCT 116
and BxPC-3 tumor cells following chemotherapy treatment. (b) Marker virus
susceptibility of sorted senescent H1299 cell-based surface CAR expression.
Sorted cells (1 10
5) with either low (R1) or high CAR (R2) expression were
re-infected with Adv-RFP and resultant RFP expression measured by FACS and
gated results reported. (c) Adenoviral marking of H1299 cells examined in the
presence of blocking anti-CAR antibody. Linear regression analysis of Adv-RFP
marking fraction and logarithmic antibody concentrations is shown. Each of these
experiments has been performed in duplicate (N¼2)
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Cell Death and Diseaseescape colony formation between marked and unmarked
states, and the progressive decline of adenoviral suscepti-
bility in senescent cells raise the possibility that cells arrested
initially in a marked state are steadily converted to an
unmarked state. To examine this hypothesis, we performed a
tandem adenoviral marking experiment (Figure 5c) where
untreated and treated H1299 tumor cells were initially
marked with Adv-RFP and re-infected with a second
marker virus, Adv-GFP, at a subsequent time. The
re-infection efﬁciency was determined as the percentage of
dual RFP/GFP-expressing cells within the gated RFP-
expressing cells. As shown in Figure 5c, untreated H1299
cells can be re-infected with Adv on successive days without
signiﬁcant loss of viral infectivity. The efﬁciency of the second
infection remained 490% at 6 days following the primary
infection. When the second infection with Adv-GFP was
carried out on CPT-treated senescent cells, the efﬁciency of
the second viral marking declined to 63 and 33% on days 4
and 6, respectively. This reduction in viral efﬁciency suggests
that cells susceptible to Adv during early therapy-induced
senescence become progressively resistant to Adv during
late senescence. Altogether, the results in Figure 5 suggest
that a transition occurs during therapy-induced senescence,
in which arrested senescent cells are converted from a
permissive state of senescence escape and cell cycle
re-entry to a restricted state with reinforced cell cycle
arrest. Escape from senescence therefore occurs
predominately during the earlier state as deﬁned by CAR
expression and adenoviral susceptibility.
We also examined the possibility that CAR expression, and
therefore, adenoviral susceptibility may preferentially select a
subpopulation of tumor cells that are resistant to chemo-
therapy. To address this possibility, we studied ﬁve con-
secutive escape colonies derived from sorted, marked
senescent cells and found that all ﬁve colonies exhibited
similar senescence responses and SA-b-gal expression
(Supplementary Figure). These senescent escape colonies
were previously shown to be equally sensitive to chemother-
apy as compared with the parental line.
19
Magnitude of irreversibility conversion determines the
frequency of senescence escape. We postulated that the
magnitude of surface CAR reduction or adenoviral marking
could serve as a potential biomarker for therapy-induced
senescence. This hypothesis was examined in vitro by
determining whether the fraction of Adv-RFP marking on day
4 could be modulated by the initial dose of chemotherapy and
whether this effect correlated with escape colony formation
(Supplementary Figure 5). H1299 tumor cells were treated
with increasing concentrations of CPT (15–150nM) for
3 days, recovered in fresh media and infected with
Adv-RFP on day 4. The relationship between colony
formation and adenoviral marking was examined using a
linear regression analysis, resulting in an r
2 coefﬁcient of
0.918 (Figure 6). This ﬁnding provides evidence that
adenoviral marking, and likely CAR expression, could serve
as a surrogate tumor biomarker to predict the magnitude and
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Figure 4 Cell cycle correlation of CAR expression and Adv marking. (a) Proliferative H1299 cells were marked with Adv-GFP or stained with CAR before ﬁxation and
stained with propidium iodide. FACS gates were set to determine adenoviral marking or CAR expression of total (ungated), G1 and G2/M cell fractions. (b) H1299 cells were
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Cell Death and Diseasedurability of senescence response during chemotherapy
treatment.
Decline in adenoviral marking is inﬂuenced by p53
status in cancer cell lines. To assess whether the decline
in adenoviral marking observed during therapy-induced
senescence is tumor-type speciﬁc or inﬂuenced by p53
status, we characterized the senescence response in
13 independent tumor lines, seven of which are wild type
for the p53 gene (Table 1). Decline in adenoviral marking is
deﬁned as a consecutive reduction of marker Adv infectivity
3 and 6 days following chemotherapy. We found that nine out
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Cell Death and Diseaseof 13 cancer cell lines exhibited decline of adenoviral marking
during senescence, including six out of seven p53-wild-type
tumor lines and three out of six p53-mutated or inactivated
lines. Two p53-mutated tumor cell lines (CAMA-1 and HT29)
showed insigniﬁcant baseline adenoviral susceptibility. All
tested cell lines displayed evidence of senescence response
based on their expression of SA-b-gal. In summary, cell lines
with the highest SA-b-gal expression were found to be
associated with the greatest baseline adenoviral marking.
Our limited data suggest that both adenoviral marking and
CAR downregulation may be more common in a p53-wild-
type background.
CAR expression is downregulated in human rectal
cancers treated with neoadjuvant chemoradio-
therapy. Tumors resected from patients diagnosed with
colorectal cancer were studied for CAR expression using
anti-CAR antibody and FITC immunostaining (Figure 7).
Tumor and adjacent normal tissues samples were collected
from patients who underwent either chemoradiotherapy
before surgery (lower panels) or surgery alone (upper
panels). The freshly frozen tissues were examined for CAR
expression. We found signiﬁcantly less visible CAR staining
in tumors resected from two patients treated with
preoperative chemoradiotherapy compared with tumor
samples from two patients who underwent surgery alone.
Furthermore, CAR expression appeared unchanged in the
normal colorectal mucosal tissue in all four patients
regardless of previous chemotherapy treatment, thereby
suggesting that differential CAR expression and staining
patterns are tumor speciﬁc. To determine whether this is a
CAR-speciﬁc treatment effect, we used a common
pathological marker for epithelial neoplasms, cytokeratin 20
(CK20) and performed immunostaining of rectal tumor
biopsies from patient C (Figure 7) obtained before and after
chemoradiation and observed no difference in CK20
expression (Supplementary Figure 7).
32 This provocative
ﬁnding in colorectal cancer patients suggests that CAR
expression should be explored as an in vivo therapy-induced
senescence biomarker in gastrointestinal cancer.
Discussion
In vivo cancer therapy response has been described as a
heterogeneous mixture of apoptosis, mitotic catastrophe,
autophagy, necrosis and therapy-induced senescence.
33
Among these, therapy-induced senescence, characterized
by prolonged cellular arrest, provides the most plausible
explanation for the modest radiographic response typically
observed in patients with solid tumors receiving chemo-
therapy.
1,34 Non-operable solid tumors predictably recur in
nearly all patients regardless of the extent of chemotherapy
response, and this fact can be further explained by the ability
of some therapy-induced senescent cells to circumvent and
escape the terminal arrest program, resulting in tumor
proliferation. In this study, we show that senescent cells in
response to chemotherapy treatment can exist in two distinct
transitional states functionally differentiated by their ability to
re-enter the cell cycle. These states can be distinguished by
their susceptibility to Adv transduction and characterized
by the levels of surface CAR expression. The transition from a
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Figure 6 Linear correlation of adenoviral marking and colony formation based
on dose effect: H1299 cells were treated with increasing CPT doses to generate a
senescent pool for colony formation assay and simultaneously infected with
Adv-RFP and analyzed by FACS for marker expression. Mean values from three
experiments were plotted and linear regression analysis was performed with an
r
2 correlation of 0.918
Table 1 Characterization of adenoviral marking and senescence response in tumor cell lines
Chemotherapy SA-b-gal
Adv marking (%)
a
Cell line Tumor origin p53 status dose expression Baseline Decline (6 day)
A549 Lung wt CPT 100nM ++++ 87 Y
H1299 Lung null CPT 60nM ++++ 92 Y
MCF7 Breast wt Dox 25nM ++ 26 Y
CAMA-1 Breast mut CPT 250nM + o2N A
b
BxPC-3 Pancreas wt CPT 200nM ++ 68 Y
PANC-1 Pancreas mut CPT 120nM ++ 75 Y
HCT 116 Colorectal wt CPT 40nM ++++ 78 Y
LoVo Colorectal wt CPT 1nM + 20 Y
SW48 Colorectal wt CPT 10nM ++ 23 N
LS174T Colorectal wt Oxali 1mM +++ 15 Y
FET Colorectal mut CPT 400nM + 10 N
HT29 Colorectal mut CPT 10nM + 6 NA
b
HeLa Cervical Inactivated Dox 600nM +++ 69 Y
Abbreviations: wt, wild type; mut, mutant; CPT, camptothecin; Dox, doxorubicin; Oxali, oxaliplatin; NA, not applicable.
aAdenoviral marking determined by FACS
(described in Figure 2).
bUntreated baseline marking o10% considered insufﬁcient to assess decline (all FACS experiments associated with 10% variability)
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Cell Death and Disease‘reversible’ to an ‘irreversible’ state therefore represents a
signiﬁcant biological barrier within senescence. Overcoming
this barrier commits senescent cells to terminal arrest and
eventual cell death. A small subpopulation of senescent
cancercellsfailstoundergothistransitionandthusretainsthe
capacity to re-enter the cell cycle leading to tumor progres-
sion.Itislikelythatthemagnitudeofthebiologicaltransitionto
irreversibility represents a functional determinant of treatment
efﬁcacy. Such a senescence barrier has been previously
described in SVts8 ﬁbroblast cells where the p16
INK4a/Rb
DAPI CAR Merged
Normal
Tumor
Normal
Tumor
Normal
Tumor
Normal
Tumor
Patient C
s/p CTX/XRT
Patient D
s/p CTX/XRT
Patient B
untreated
Patient A
untreated
Figure 7 CARexpressionincolorectal adenocarcinomafollowingchemoradiotherapy:humantumorandadjacentnormaltissuespecimenswereobtainedfromcolorectal
cancer patients undergoing curative resection treated with or without preoperative chemotherapy and radiation (CTX/XRT). Freshly frozen specimens were stained with CAR
primary antibody (Santa Cruz) followed with FITC-conjugated secondary antibody or with DAPI. Immunoﬂuorescence micrographs ( 40) of CAR, DAPI and merged images
are shown
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Cell Death and Diseasepathway appears to cooperate with mitogenic signals to
enforce an irreversible block of cytokinesis through the
productionofreactiveoxygenspecies.
35Thebiologicalbarrier
in H1299 cancer cells is presently unknown as p16
INK4a is
silenced in these cells.
19
Theefﬁcacyofincreasingdrugdoseinchemotherapyforms
the theoretical basis for dose intensity in cancer therapeu-
tics.
36 However, dose escalation is limited by normal tissue
tolerance as well as the failure of dose escalation to eradicate
all disease. Indeed, clinical trials utilizing high-dose chemo-
therapy for solid tumors have been largely ineffective with
limited clinical beneﬁt.
36 In this study, we show that escalating
CPT dose reduces both the population of reversibly arrested
senescent cells and the formation of escape colonies. This
observation suggests that the magnitude and rate of conver-
sion to irreversible therapy-induced senescence can be
modulated by dose intensity and quantiﬁed by CAR expres-
sion; however, even a 10-fold increase of chemotherapy
cannot overcome the ability of some senescent cells to
circumvent conversion to irreversible arrest. Taken together
this suggests a potential role for biomarkers to assess in vivo
senescence response. An appealing candidate marker is
CAR, which is ubiquitously expressed on the surface of most
epithelial tumors, including prostate, endometrial and other
common gastrointestinal malignancies.
25,37,38 The level of
CAR expression, however, appears to vary widely depending
on tissue type and histological grade of the tumor. The
demonstration of surface CAR downregulation in human
tumor specimens following preoperative chemotherapy treat-
ment closely parallels expression proﬁles characterized in
tissue culture models. Thus, chemotherapeutic modulation of
CAR expression could be studied as a surrogate biomarker
for senescence response.
We also propose that CAR expression can be used as a
novel methodology for the isolation of senescent cell
subpopulations with characteristic biological states based on
their ability to re-enter the cell cycle and likely represent
cells in either reversible or irreversible transition states. The
approach outlined here should enable comparative studies of
early molecular events that regulate senescence reversibility.
Understanding these cellular events may unveil mechanisms
by which cancers can bypass this critical transition in therapy-
induced senescence. One such example is the role of
telomere disruption and telomerase regulation in senescent
tumor cells. We have found that therapy-induced senescent
cells are frequently accompanied by signiﬁcant telomere loss.
In preliminary experiments, we have observed that senescent
cells, which are able to escape arrest and regain proliferative
capacity, partially recover the lost telomere. These prelimin-
ary results suggest that telomere disruption and recovery may
be an underlying mechanism of the irreversibility barrier.
This hypothesis is supported by the ﬁnding of signiﬁcantly
higher telomerase activity in Adv marked senescent cells
compared with unmarked cells (Supplementary Figure 6).
Our report illustrates the utility of CAR expression and
adenoviral marker transduction as convenient methodologies
to study fundamental regulatory mechanisms in therapy-
induced senescence. Successful application of this approach
to characterize transitional states in cancer senescence
may lead to the discovery of potential drug targets and
novel therapeutic strategies to improve cancer clinical
outcomes.
Materials and Methods
Cell culture. NCI-H1299 (H1299) lung carcinoma (ATCC, Manassas, VA, USA)
and BxPC-3 pancreatic adenocarcinoma (ATCC) cells were cultured in RPMI 1640
supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin
(BioWhittaker, Walkersville, MD, USA). HCT 116 colon carcinoma cells (ATCC)
were cultured in McCoy’s 5a medium supplemented with 10% fetal bovine serum
and 1% penicillin/streptomycin. Cells were treated with chemotherapy at 15% to
30% cell density for 1–3 days, rinsed with PBS and allowed to recover at indicated
times in complete growth medium for speciﬁc assays. H1299 and BxPC-3 cells
were treated with CPT and HCT 116 was treated with doxorubicin at indicated
concentrations and recovered as shown in the schema (Figure 1a). G1 arrest was
induced in H1299 cells by serum starvation in RPMI with 0.5% FBS for 72h,
whereasG2/MarrestwasinducedbytreatingH1299cellswith20nMnocodazolefor
16–24h (Sigma-Aldrich, St Louis, MO, USA). The cancer cell lines including LoVo,
SW48, LS174T and FET were provided as a kind gift from Dr. William Grady (Fred
HutchinsonCancerResearchCenter,Seattle,WA,USA)andHT29wasagenerous
gift from Dr. Steven Libutti (NCI/NIH, Bethesda, MD, USA). The remaining cell lines
including A549, MCF7, CAMA-1, PANC-1 and HeLa were obtained from ATCC.
Construction and expression of marker Adv. RNAi-ready pSiren-
DNR-DsRed-Express vector was obtained from Clontech (Mountain View, CA,
USA), which contains the RFP. For our purpose, we annealed the linearized vector
by T4 DNA ligase without an insert and transferred the RFP ﬂuorescent marker to
adenoviral X-acceptor vector by cre recombinase according to the manufacturer’s
protocol (AdenoX kit; Clontech). The recombinant viral vector was screened
and ampliﬁed in Escherichia coli, packaged and ampliﬁed in HEK 293 as per the
manufacturer’s instruction. Adv containing the LacZ gene was constructed as per
the manufacturer’s instructions (AdenoX kit; Clontech) and Adv containing
enhanced GFP was a kind gift from Dr. Liu Yang (University of Washington,
Seattle, WA, USA).
Immunoﬂuorescence microscopy. Adv-RFP, Adv-GFP and CAR
expression were detected by ﬂuorescence microscopy (Nikon eclipse E-800). For
Adv-RFP or Adv-GFP expression, tumor cells were incubated in multi-chamber
slides with marker Adv for 4h, washed in PBS and replaced in respective complete
growth medium. After overnight incubation, cells were washed and ﬁxed in 1%
paraformaldehyde. The cells were then permeabilized with 0.2% Triton X-100 and
stained with 0.2% DAPI solution and examined under the ﬂuorescence microscope.
For CAR expression, cells were incubated in multi-chamber slides with anti-CAR
antibodyat1:50dilutionin1%BSA/PBS(Abcam,Cambridge,MA,USA)for1hand
further incubated with FITC-conjugated anti-mouse secondary antibody (1:200).
After ﬁxation in 1% paraformaldehyde, the cells were examined using ﬂuorescence
microscopy. Tumor and normal tissue samples were collected from colorectal
cancer patients undergoing elective resection following standard informed consent
and protocols approved by the VA Puget Sound Human Subjects Institutional
Research Board (IRB No. 01468, Colorectal Cancer Treatment and Cellular
Senescence). Tumor and tissue samples were freshly frozen in Tissue-Tek OCT
(Sakura Finetek, Alphen aan den, the Netherlands), cryosectioned and
immunostained with anti-CAR (Santa Cruz Biotechnology, Santa Cruz, CA, USA)
and FITC-conjugated secondary antibody as described above.
FACS analysis and cell sorting. RFP-, GFP- and CAR-expressing cells
were analyzed and sorted by FACS (Becton-Dickinson FACS caliber). Tumor cells
used in adenoviral marking experiments were incubated with Adv for 4h, washed
with PBS and recovered in complete growth medium. After overnight recovery, the
cells were collected, ﬁxedin 1% paraformaldehyde and analyzedby ﬂow cytometry.
For CAR expression analysis, the cells were collected and incubated with 1:50
mouse anti-CAR antibody (Abcam) in 1% BSA/PBS for 1h and with 1:200
secondary FITC anti-mouse antibody for 30min without ﬁxation. The expression
of CAR was detected by FACS analysis. In the FACS sorting experiments,
tumor cells were treated as previously described following Adv infection or CAR
immunostaining, sorted and collected in 50ml Falcon tubes pre-coated with
4% BSA/PBS. Cell suspensions were concentrated by centrifugation at 1500r.p.m.
for 5min and resuspended in complete growth medium for further analysis.
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Cell Death and DiseaseMTT cell proliferation assay. Treated H1299tumor cells were infectedwith
Adv-RFP and FACS sorted into ‘marked’ and ‘unmarked’ cell populations. MTT cell
proliferation assays were performed on serial dilutions of these cell populations
ranging from 1 10
3 to 1 10
6 cells according to the manufacturer’s
recommendations (ATCC). Absorbance at 570nm was measured from triplicate
plates using a microtiter plate reader.
Colony formation assay and staining. The cells were infected with
Adv-RFP on day 4 following chemotherapy and sorted according to their RFP
expression. Indicated numbers of sorted cells were replated in complete growth
mediumandallowedtoformcoloniestypicallyobservedafter10–17days.Theplate
colonies were then ﬁxed in 1% paraformaldehyde, stained with 0.2% trypan blue,
scannedandcountedusinganAlphaImagersystem(CellBiosciences,SantaClara,
CA, USA). In situ X-gal assay was performed at pH 7.0 as per the manufacturer’s
recommendation (Promega, Madison, WI, USA). SA-b-gal in situ staining was
performed as we have reported previously.
19
Image processing and reproduction. Images of gel and digital
photographs were generated with Adobe Photoshop CS4 and Illustrator CS4.
Statistical analysis. Statistical analysis was performed as speciﬁed using
Microsoft Ofﬁce 2007 package.
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